Biotech start-ups tout plans for microRNA and cardio drugs

A pair of biotech start-ups raised their flags this morning. Out in Seattle, Mirina announced that it had raised an undisclosed amount of money in a Series A-1 that would cover its burn rate for the next 12 to 15 months. And a new start-up dubbed LipimetiX has announced its debut in Boston. Versant Ventures led the round for Mirina, which will use the money--however much it is--to further explore development of microRNA therapies. Xconomy notes that while Mirina is keeping the financial details...